However, the key point of our research is another: even if other genes found in the same physical region of SQLE have their own roles in determining an aggressive cancer phenotype, we have also showed experimentally that SQLE is an attractive bona fide target for treatment, while other co-located proteins (such as RAD21) are not readily druggable, and hence less clinically relevant to the purpose of finding novel therapeutic targets in breast cancer and other tumor types. This evidence concerns the gene RAD21 and cancer.